Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fortress Biotech (FBIO) Gross Margin: 2013-2025

Historic Gross Margin for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to 67.36%.

  • Fortress Biotech's Gross Margin fell 208.00% to 67.36% in Q3 2025 from the same period last year, while for Sep 2025 it was 67.64%, marking a year-over-year decrease of 285.00%. This contributed to the annual value of 63.80% for FY2024, which is 911.00% down from last year.
  • Latest data reveals that Fortress Biotech reported Gross Margin of 67.36% as of Q3 2025, which was down 3.65% from 69.91% recorded in Q2 2025.
  • Fortress Biotech's 5-year Gross Margin high stood at 88.73% for Q4 2023, and its period low was 47.04% during Q3 2021.
  • Moreover, its 3-year median value for Gross Margin was 67.36% (2025), whereas its average is 66.22%.
  • Per our database at Business Quant, Fortress Biotech's Gross Margin tumbled by 2,098bps in 2021 and then surged by 3,578bps in 2023.
  • Quarterly analysis of 5 years shows Fortress Biotech's Gross Margin stood at 47.88% in 2021, then spiked by 507bps to 52.95% in 2022, then skyrocketed by 3,578bps to 88.73% in 2023, then crashed by 1,968bps to 69.05% in 2024, then crashed by 208bps to 67.36% in 2025.
  • Its Gross Margin was 67.36% in Q3 2025, compared to 69.91% in Q2 2025 and 63.54% in Q1 2025.